{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:02:04Z","timestamp":1780020124893,"version":"3.53.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["RCCCDF-May24\/100001"],"award-info":[{"award-number":["RCCCDF-May24\/100001"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR301614"],"award-info":[{"award-number":["NIHR301614"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.jp","oarsiopenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ocarto.2026.100777","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:35:55Z","timestamp":1773189355000},"page":"100777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adaptive trials in low back pain and osteoarthritis: How common are they and when should they be used? A systematic review from ClinicalTrials.gov"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2179-3620","authenticated-orcid":false,"given":"Anelise Moreti Cabral","family":"Silveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7434-6132","authenticated-orcid":false,"given":"Michelle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2024-4945","authenticated-orcid":false,"given":"Michelle","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3479-0683","authenticated-orcid":false,"given":"Manuela L.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3986-6111","authenticated-orcid":false,"given":"Paula R.","family":"Beckenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4670-0638","authenticated-orcid":false,"given":"Thomas","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-5544","authenticated-orcid":false,"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4975-9793","authenticated-orcid":false,"given":"Laurent","family":"Billot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-126X","authenticated-orcid":false,"given":"James M.S.","family":"Wason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-2117","authenticated-orcid":false,"given":"Haiyan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5861-7770","authenticated-orcid":false,"given":"Paulo H.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ocarto.2026.100777_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062183","article-title":"Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the global burden of disease 2019 study","volume":"12","author":"Liu","year":"2022","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.ocarto.2026.100777_bib2","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/S2665-9913(23)00098-X","article-title":"Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"9","key":"10.1016\/j.ocarto.2026.100777_bib3","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast. Reconstr. Surg."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7167","key":"10.1016\/j.ocarto.2026.100777_bib6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.317.7167.1236","article-title":"Efficient management of randomised controlled trials: nature or nurture","volume":"317","author":"Farrell","year":"1998","journal-title":"BMJ"},{"issue":"9912","key":"10.1016\/j.ocarto.2026.100777_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(13)62229-1","article-title":"How to increase value and reduce waste when research priorities are set","volume":"383","author":"Chalmers","year":"2014","journal-title":"Lancet"},{"issue":"9683","key":"10.1016\/j.ocarto.2026.100777_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","article-title":"Avoidable waste in the production and reporting of research evidence","volume":"374","author":"Chalmers","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ocarto.2026.100777_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012754","article-title":"The carbon footprint of clinical trials: a global survey on the status quo and current regulatory guidance","volume":"8","author":"Hoffmann","year":"2023","journal-title":"BMJ Glob. Health"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med."},{"issue":"k698","key":"10.1016\/j.ocarto.2026.100777_bib11","article-title":"Key design considerations for adaptive clinical trials: a primer for clinicians","volume":"360","author":"Thorlund","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.ocarto.2026.100777_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106096","article-title":"Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies","volume":"98","author":"Li","year":"2020","journal-title":"Contemp. Clin. Trials"},{"issue":"6","key":"10.1016\/j.ocarto.2026.100777_bib14","first-page":"376","article-title":"Adaptive trial designs: what are multiarm, multistage trials?","volume":"105","author":"Millen","year":"2020","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12916-019-1391-9","article-title":"When to keep it simple - adaptive designs are not always useful","volume":"17","author":"Wason","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.ocarto.2026.100777_bib16","series-title":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)","first-page":"33","article-title":"Adaptive designs for clinical trials of drugs and biologics - Guidance for Industry","year":"2019"},{"key":"10.1016\/j.ocarto.2026.100777_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.wneu.2021.07.061","article-title":"Adaptive designs: benefits and cautions for neurosurgery trials","volume":"161","author":"Mukherjee","year":"2022","journal-title":"World Neurosurg."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1745-6215-15-61","article-title":"An investigation of the impact of futility analysis in publicly funded trials","volume":"15","author":"Sully","year":"2014","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.ocarto.2026.100777_bib19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrclinonc.2011.165","article-title":"Adaptive clinical trials in oncology","volume":"9","author":"Berry","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ocarto.2026.100777_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Zarychanski R. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ocarto.2026.100777_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/CIRCULATIONAHA.121.058113","article-title":"What are adaptive platform clinical trials and what role may they have in cardiovascular medicine?","volume":"145","author":"Lawler","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ocarto.2026.100777_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.108.809707","article-title":"Optimizing trial design","volume":"119","author":"Mehta","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12874-023-02024-1","article-title":"A systematic review of randomised controlled trials with adaptive and traditional group sequential designs \u2013 applications in cardiovascular clinical trials","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Med. Res. Methodol."},{"issue":"12","key":"10.1016\/j.ocarto.2026.100777_bib24","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1016\/S1473-3099(19)30284-1","article-title":"Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials","volume":"19","author":"Lanini","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.ocarto.2026.100777_bib25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/19466315.2020.1790415","article-title":"Efficient adaptive designs for clinical trials of interventions for COVID-19","volume":"12","author":"Stallard","year":"2020","journal-title":"Stat. Biopharm. Res."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1186\/s13063-022-06929-y","article-title":"ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial","volume":"23","author":"Denholm","year":"2022","journal-title":"Trials"},{"issue":"7","key":"10.1016\/j.ocarto.2026.100777_bib27","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/cid\/cix907","article-title":"Adaptive designs for clinical trials: application to healthcare epidemiology research","volume":"66","author":"Huskins","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ocarto.2026.100777_bib28","first-page":"45","year":"2016"},{"issue":"5","key":"10.1016\/j.ocarto.2026.100777_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/sim.8430","article-title":"Adaptive trial designs in diagnostic accuracy research","volume":"39","author":"Zapf","year":"2020","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12874-024-02272-9","article-title":"Adaptive designs in clinical trials: a systematic review-part I","volume":"24","author":"Ben-Eltriki","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"issue":"4","key":"10.1016\/j.ocarto.2026.100777_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jep.13715","article-title":"The importance of embracing complexity in rehabilitation","volume":"29","author":"Stockley","year":"2023","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.ocarto.2026.100777_bib32","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib33","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1186\/s12885-021-08965-4","article-title":"The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol","volume":"21","author":"Ursprung","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ocarto.2026.100777_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005559","article-title":"Rationale and study design of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial","volume":"4","author":"Waldron-Lynch","year":"2014","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.ocarto.2026.100777_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pst.541","article-title":"Adaptive designs for single-arm phase II trials in oncology","volume":"11","author":"Englert","year":"2012","journal-title":"Pharm. Stat."},{"issue":"3","key":"10.1016\/j.ocarto.2026.100777_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/pst.2190","article-title":"An adaptive design for early clinical development including interim decision for single-arm trial with external controls or randomized trial","volume":"21","author":"Gotte","year":"2022","journal-title":"Pharm. Stat."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s13063-023-07398-7","article-title":"On the use of non-concurrent controls in platform trials: a scoping review","volume":"24","author":"Bofill Roig","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.ocarto.2026.100777_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cct.2015.11.003","article-title":"Design of a multi-arm randomized clinical trial with no control arm","volume":"46","author":"Magaret","year":"2016","journal-title":"Contemp. Clin. Trials"},{"issue":"4","key":"10.1016\/j.ocarto.2026.100777_bib39","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jama.2022.24324","article-title":"Sequential, multiple assignment, randomized trial designs","volume":"329","author":"Kidwell","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12891-019-2510-7","article-title":"Strategies for optimising musculoskeletal health in the 21st century","volume":"20","author":"Lewis","year":"2019","journal-title":"BMC Muscoskelet. Disord."},{"issue":"6","key":"10.1016\/j.ocarto.2026.100777_bib41","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2106\/JBJS.22.00693","article-title":"A call to action for musculoskeletal research funding: the growing economic and disease burden of musculoskeletal conditions in the United States is not reflected in musculoskeletal research funding","volume":"105","author":"McConaghy","year":"2023","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ocarto.2026.100777_bib42","article-title":"Musculoskeletal health: an ecological study assessing disease burden and research funding","volume":"29","author":"Nguyen","year":"2024","journal-title":"Lancet Reg. Health, Am."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12916-021-02124-z","article-title":"Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the costing adaptive trials project","volume":"19","author":"Wilson","year":"2021","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12874-024-02339-7","article-title":"Reporting and communication of sample size calculations in adaptive clinical trials: a review of trial protocols and grant applications","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"issue":"7","key":"10.1016\/j.ocarto.2026.100777_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-098324","volume":"15","author":"Silveira","year":"2025","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13063-019-3578-y","article-title":"Progression criteria in trials with an internal pilot: an audit of publicly funded randomised controlled trials","volume":"20","author":"Herbert","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13063-016-1493-z","article-title":"Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project","volume":"17","author":"Meurer","year":"2016","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1186\/s13063-015-1119-x","article-title":"Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials","volume":"16","author":"Dimairo","year":"2015","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.ocarto.2026.100777_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/2168479014522468","article-title":"Adaptive design: results of 2012 survey on perception and use","volume":"48","author":"Morgan","year":"2014","journal-title":"Therapeutic Innovation & Regulatory Science"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1467-9868.2012.01030.x","article-title":"Group sequential tests for delayed responses (with discussion)","volume":"75","author":"Hampson","year":"2013","journal-title":"J. Roy. Stat. Soc. B"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib51","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1186\/s13063-021-05818-0","article-title":"Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada","volume":"22","author":"Briel","year":"2021","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.ocarto.2026.100777_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/pst.472","article-title":"An adaptive seamless phase II\/III design for oncology trials with subpopulation selection using correlated survival endpoints","volume":"10","author":"Jenkins","year":"2011","journal-title":"Pharm. Stat."},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41597-020-00780-z","article-title":"Obstacles to the reuse of study metadata in clinicalTrials.gov","volume":"7","author":"Miron","year":"2020","journal-title":"Sci. Data"},{"issue":"1","key":"10.1016\/j.ocarto.2026.100777_bib54","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13063-016-1273-9","article-title":"Adaptive designs undertaken in clinical research: a review of registered clinical trials","volume":"17","author":"Hatfield","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.ocarto.2026.100777_bib55","article-title":"The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design","volume":"369","author":"Dimairo","year":"2020","journal-title":"Br. Med. J."}],"container-title":["Osteoarthritis and Cartilage Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266591312600035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266591312600035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:08:06Z","timestamp":1780016886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266591312600035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S266591312600035X"],"URL":"https:\/\/doi.org\/10.1016\/j.ocarto.2026.100777","relation":{},"ISSN":["2665-9131"],"issn-type":[{"value":"2665-9131","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptive trials in low back pain and osteoarthritis: How common are they and when should they be used? A systematic review from ClinicalTrials.gov","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ocarto.2026.100777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International (OARSI).","name":"copyright","label":"Copyright"}],"article-number":"100777"}}